Lebrikizumab: a novel approach in managing atopic dermatitis in pediatric patients
DOI:
https://doi.org/10.18203/2349-3291.ijcp20233511Keywords:
Atopic dermatitis, Lebrikizumab, Skin disease, Dermatology, PediatricsAbstract
Atopic dermatitis is a prominent dermatological condition in children that frequently affects their lifestyle. Conventional treatments frequently prove inadequate, necessitating the use of biological agents like Lebrikizumab to address the condition at its core pathophysiological level. The introduction of biologic drugs has broadened the spectrum of treatment options for patients with moderate to severe atopic dermatitis, especially those who have not achieved satisfactory results with conventional monotherapy or combination therapies, or those with contraindications to systemic immunosuppressive agents. Lebrikizumab appears to be a promising option for the treatment of atopic dermatitis, showing a strong response in clinical trials. It offers the potential for improved long-term efficacy and a reduction in adverse effects. This article provides an overview of Lebrikizumab's role in addressing the pathogenesis of atopic dermatitis and highlights its current advancements.
References
Labib A, Ju T, Yosipovitch G. Managing Atopic Dermatitis with Lebrikizumab - The Evidence to Date. Clin Cosmet Investig Dermatol. 2022;15:1065-72.
Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, et al. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study. Dermatol Ther. 2022;13(7):1517-34.
Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022;150(3):690-700.
Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7): 756-68.
Bernardo D, Bieber T, Torres T. Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2023;24(5):753-64.
Napolitano M, Fabbrocini G, Martora F, Genco L, Noto M, Patruno C. Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022;35(12):e15901.
Gür Çetinkaya P, Şahiner ÜM. Childhood atopic dermatitis: current developments, treatment approaches, and future expectations. Turk J Med Sci. 2019;49(4):963-84.
Munera-Campos M, Carrascosa JM. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment. Actas Dermosifiliogr. 2020;111(3):205-21.
Aldredge A, Lakshi M. Atopic dermatitis with a focus on moderate to severe disease. J Nurse Pract. 2020; 16(10):726-73.
Zhou S, Qi F, Gong Y, Zhang J, Zhu B. Biological therapies for atopic dermatitis: a systematic review. Dermatology. 2021;237(4):542-52.
Eichenfield LF, Stripling S, Fung S, Cha A, O'Brien A, Schachner LA. Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. Paediatr Drugs. 2022;24(4):293-305.
Saini S, Pansare M. New Insights and Treatments in Atopic Dermatitis. Pediatr Clin North Am. 2019; 66(5):1021-33.
Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R. Updated Review on Treatment of Atopic Dermatitis. J Investig Allergol Clin Immunol. 2023;33(3):158-67.
Loh TY, Hsiao JL, Shi VY. Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis. J Asthma Aller. 2020;13:109-14.
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797-810.
Kondratuk K, Netravali IA, Castelo-Soccio L. Modern interventions for pediatric atopic dermatitis: an updated pharmacologic approach. Dermatol Ther. 2023;13(2):367-89.
Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. JAMA Dermatol. 2020;156(4):411-20.
Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. Am Fam Physic. 2020;101(10):590-8.
Stein Gold L, Thaçi D, Thyssen JP, Gooderham M, Laquer V, Moore A, et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Am J Clin Dermatol. 2023;24(4):595-607.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023;388(12):1080-91.
Butala S, Paller AS. Biologics in the management of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(3):681-5.
Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2): 182-91.
Bashrahil B, Alzahrani Z, Samarkandy S, Aman A, Jfri A. The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Front Med. 2023;9:109.
Caffarelli C, Giannetti A, Giannì G, Ricci G. Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents. Front Med. 2023;10:121.
